Therapeutic strategy for progressive renal disease

K. Hayashi, Y. Ozawa, Hirobumi Tokuyama

Research output: Contribution to journalArticle

Abstract

Renal disease constitutes an important determinant of cardiovascular disease. Although the mechanisms for the progression of renal impairment remain fully undetermined, available evidence indicate that renal glomerular hypertension is responsible in part for the development of renal injury. In renal disease, afferent arteriolar tone is reported to be reduced, while the augmented intrarenal angiotensin II serves to act as an efferent arteriolar constrictor, both of which result in an increase in glomerular capillary pressure. Angiotensin converting enzyme inhibitors (ACE-I) are established as the agent possessing both antihypertensive and renoprotective actions, which exert vasodilator action on efferent arterioles. Calcium antagonists are also reported to have salutary effect on renal disease, although their beneficial action varies depending on the antagonists used and the underlying disease. The use of calcium antagonists, however, is mandatory particularly under the circumstance where renal failure moderately to severely progresses and the ACE-I cannot be used.

Original languageEnglish
Pages (from-to)955-960
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume59
Issue number5
Publication statusPublished - 2001

Fingerprint

Kidney
Angiotensin-Converting Enzyme Inhibitors
Calcium
Therapeutics
Renal Hypertension
Arterioles
Vasodilator Agents
Angiotensin II
Antihypertensive Agents
Renal Insufficiency
Cardiovascular Diseases
Pressure
Wounds and Injuries

Cite this

Therapeutic strategy for progressive renal disease. / Hayashi, K.; Ozawa, Y.; Tokuyama, Hirobumi.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 59, No. 5, 2001, p. 955-960.

Research output: Contribution to journalArticle

@article{bd0996792ea346f9ab4258d031d633f1,
title = "Therapeutic strategy for progressive renal disease",
abstract = "Renal disease constitutes an important determinant of cardiovascular disease. Although the mechanisms for the progression of renal impairment remain fully undetermined, available evidence indicate that renal glomerular hypertension is responsible in part for the development of renal injury. In renal disease, afferent arteriolar tone is reported to be reduced, while the augmented intrarenal angiotensin II serves to act as an efferent arteriolar constrictor, both of which result in an increase in glomerular capillary pressure. Angiotensin converting enzyme inhibitors (ACE-I) are established as the agent possessing both antihypertensive and renoprotective actions, which exert vasodilator action on efferent arterioles. Calcium antagonists are also reported to have salutary effect on renal disease, although their beneficial action varies depending on the antagonists used and the underlying disease. The use of calcium antagonists, however, is mandatory particularly under the circumstance where renal failure moderately to severely progresses and the ACE-I cannot be used.",
author = "K. Hayashi and Y. Ozawa and Hirobumi Tokuyama",
year = "2001",
language = "English",
volume = "59",
pages = "955--960",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "5",

}

TY - JOUR

T1 - Therapeutic strategy for progressive renal disease

AU - Hayashi, K.

AU - Ozawa, Y.

AU - Tokuyama, Hirobumi

PY - 2001

Y1 - 2001

N2 - Renal disease constitutes an important determinant of cardiovascular disease. Although the mechanisms for the progression of renal impairment remain fully undetermined, available evidence indicate that renal glomerular hypertension is responsible in part for the development of renal injury. In renal disease, afferent arteriolar tone is reported to be reduced, while the augmented intrarenal angiotensin II serves to act as an efferent arteriolar constrictor, both of which result in an increase in glomerular capillary pressure. Angiotensin converting enzyme inhibitors (ACE-I) are established as the agent possessing both antihypertensive and renoprotective actions, which exert vasodilator action on efferent arterioles. Calcium antagonists are also reported to have salutary effect on renal disease, although their beneficial action varies depending on the antagonists used and the underlying disease. The use of calcium antagonists, however, is mandatory particularly under the circumstance where renal failure moderately to severely progresses and the ACE-I cannot be used.

AB - Renal disease constitutes an important determinant of cardiovascular disease. Although the mechanisms for the progression of renal impairment remain fully undetermined, available evidence indicate that renal glomerular hypertension is responsible in part for the development of renal injury. In renal disease, afferent arteriolar tone is reported to be reduced, while the augmented intrarenal angiotensin II serves to act as an efferent arteriolar constrictor, both of which result in an increase in glomerular capillary pressure. Angiotensin converting enzyme inhibitors (ACE-I) are established as the agent possessing both antihypertensive and renoprotective actions, which exert vasodilator action on efferent arterioles. Calcium antagonists are also reported to have salutary effect on renal disease, although their beneficial action varies depending on the antagonists used and the underlying disease. The use of calcium antagonists, however, is mandatory particularly under the circumstance where renal failure moderately to severely progresses and the ACE-I cannot be used.

UR - http://www.scopus.com/inward/record.url?scp=0035344964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035344964&partnerID=8YFLogxK

M3 - Article

C2 - 11391998

AN - SCOPUS:0035344964

VL - 59

SP - 955

EP - 960

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 5

ER -